A Prospective Phase Ⅰ Clinical Study of Docetaxel with Concurrent Late-course Hyperfractionated Radiotherapy After Breast-conserving Surgery for Stage T1-T2 Breast Cancer
10.3971/j.issn.1000-8578.2022.21.1295
- VernacularTitle:T1~T2期乳腺癌保乳术后化疗后程同步大分割放疗前瞻性Ⅰ期临床研究
- Author:
Yudi XIONG
1
;
Xue ZHANG
;
Ning ZOU
;
Jingjing MOU
;
Benhui LI
;
Weidong CHEN
;
Lingxia LIAO
;
Jiucheng ZHANG
Author Information
1. Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China
- Publication Type:Research Article
- Keywords:
Breast cancer;
Breast-conserving operation;
Hyperfractionated radiotherapy;
Postoperative chemotherapy;
Health economics
- From:
Cancer Research on Prevention and Treatment
2022;49(10):1054-1058
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate prospectively the side effects and tolerance of docetaxel with concurrent late-course hyperfractionated radiotherapy after breast-conserving surgery for stage T1-T2 breast cancer, and to assess the value of this treatment in shortening the treatment time and reducing the economic burden among patients. Methods A total of 20 patients with T1-T2 breast cancer were recruited after they underwent breast-conserving surgery. The acute radiation response classification, treatment completion rate, disease-free survival, hospital stays, and treatment costs were observed. Radiotherapy for all patients was started before the last single-agent docetaxel chemotherapy. Results The completion rate of treatment and the good rate of cosmetic effect reached 100%. The main adverse reactions were hematological toxicity (leukopenia) and skin reactions, which were tolerated. The median follow-up time was 30.1 months, and the follow-up rate was 100%. The average total treatment time of this hyperfractionated radiotherapy with concurrent docetaxel was four weeks, and the total hospitalization cost savings was approximately 10, 000 yuan. The 21-month disease-free survival rate was 100%. Conclusion Stage T1-T2 breast cancer can tolerate hyperfractionated radiotherapy with concurrent chemotherapy after a breast-conserving operation. The procedure results in good local control and satisfactory cosmetic effects, with high health and economic value.
